Arun B. Jesudian, MD
PeerPatricia P. Bloom, MD
PeerPatricia P. Bloom, MD
PeerArun B. Jesudian, MD
PeerRobert Rahimi, MD, MSCR
PeerClaudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
PeerWhat Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Yelena Janjigian, MD
Peer